Pulse Oximeter 510(k) Map: 726 Predicate Clearances and the FDA Pigmentation Reckoning

Executive Summary

Pulse oximeters are among the most-cleared and most-ubiquitous medical devices in clinical use — and they are now at the center of a regulatory reckoning over accuracy across skin tones. Our analysis of the complete FDA 510(k) premarket notification database for the oximeter product-code family finds a market built almost entirely on predicate-based clearances:

• Every one of the 726 pulse-oximeter (product code DQA) 510(k) clearances on record was cleared as "substantially equivalent" to an earlier predicate device — there is no standalone De Novo or PMA backbone for the conventional fingertip and reusable pulse oximeter; the entire category is a 510(k) predicate chain
• Masimo (77 clearances across its recorded entity names), Nonin Medical (42), and the Nellcor lineage (30, now Medtronic) anchor the predicate tree, with Beijing Choice (31) and BCI (18) leading the volume tier below
• Clearance volume is remarkably steady — roughly 13 to 20 DQA clearances every year from 2014 through 2025 — reflecting a mature, saturated market rather than an emerging one
• 128 pulse-oximeter recall events sit alongside the clearance record, a post-market footprint that is modest relative to infusion pumps or dialysis disposables but non-trivial for a Class II device
• FDA's January 7, 2025 draft guidance rewrites the predicate bargain: it asks manufacturers to generate clinical performance data across the range of skin pigmentation, directly responding to the 2020 Sjoding finding that pulse oximeters overestimate oxygen saturation in Black patients about three times as often as in White patients

The tension at the heart of this market is that a device family cleared entirely by equivalence to older predicates now faces evidence that those predicates' accuracy is not uniform across the patient population. Resolving that tension is what the FDA draft guidance is designed to do.

Why Pulse Oximeters Are a 510(k) Story

A pulse oximeter estimates arterial oxygen saturation (SpO₂) noninvasively by shining red and infrared light through tissue and reading the absorbance ratio. FDA classifies the device under product code DQA (Oximeter) at Class II under regulation 21 CFR 870.2700, with a small family of related codes for specialized use (tissue-saturation, ear, cerebral, and over-the-counter oximeters).

The 726 DQA clearances are the story. Since the 1980s, the conventional pulse oximeter has entered the U.S. market through the 510(k) pathway by demonstrating substantial equivalence to a predicate — typically an earlier-generation sensor or monitor from the same or a competing manufacturer. There is no PMA requirement and no standalone De Novo foundation for the category; the entire installed base rests on a chain of equivalency determinations that, in principle, reach back to the original cleared predicates.

Data Source and Method

• Sources: FDA 510(k) premarket notification database (clearances, applicants, decision, clearance type) cross-referenced to the FDA Medical Device Recall database and the FDA product classification database
• Analysis sample: 847 oximeter-family 510(k) clearance records, of which 726 are product code DQA; 128 recall records tagged to the oximeter family
• Run date: 2026-06-14
• Method: All counts were computed by MedDeviceGuide from the public FDA 510(k), recall, and classification extracts. Applicant names were consolidated where the same firm appears under multiple recorded spellings (for example, "Masimo Corporation" and "Masimo Corp."). Clearance counts reflect the FDA decision description of "Substantially Equivalent"; no DQA record carried a different decision. The recall count is for the oximeter product-code family and is not restricted to Class I.

The Predicate Tree: Who Clears Against Whom

Because every DQA clearance is a substantial-equivalence determination, the market structure is best read as a predicate tree in which a few sensor-technology leaders seed the equivalence claims of the long tail of followers. The top applicants by clearance volume:

Three structural facts stand out. First, Masimo is by some margin the most-cleared DQA applicant, reflecting its strategy of seeding the market with successive sensor generations (SET, RD SET) that then become predicates for its own and others' follow-on clearances. Second, a substantial share of clearances is held by exporters and OEM suppliers (Beijing Choice, Unimed, Epic, Shenzhen Creative, Edan) whose devices populate the consumer and over-the-counter fingertip-oximeter market that exploded during the COVID-19 pandemic. Third, the hospital-sensor tier is dominated by the Nellcor (Medtronic) and Masimo names that also set the clinical-reference standard.

Clearance volume has been steady rather than growing:

This stability is itself the signal: the pulse-oximeter market is mature, saturated, and built on incremental predicate-based clearances rather than novel technology entries. By clearance type, 574 of the 726 are Traditional 510(k)s, 140 are Special 510(k)s (manufacturer self-declared equivalence), and 12 are Abbreviated.

The Accuracy Standard the Predicates Were Built On

FDA's acceptance criterion for pulse-oximeter 510(k) clearance has long been an Arms (root-mean-square accuracy) of no more than 3% SpO₂ against arterial blood-gas (CO-oximetry) reference values, evaluated over a specified saturation range in a clinical study. That ±3% tolerance is the technical hinge on which the entire predicate chain rests — and it is also the source of the disparity problem, because a 3% tolerance that holds on average can mask systematically larger errors in a subgroup of patients.

The Racial-Bias Finding That Broke the Equilibrium

The catalyst for regulatory action was a 2020 correspondence in the New England Journal of Medicine. Sjoding and colleagues compared pulse-oximeter readings with arterial blood-gas measurements across roughly 10,000 paired measurements from inpatients at the University of Michigan and found that occult hypoxemia — a pulse-oximeter reading of 92–96% when the true arterial saturation was below 88% — occurred about three times more often in Black patients than in White patients (Sjoding et al., NEJM 2020). Roughly 12% of Black patients in the cohort had a pulse-oximeter reading that overestimated their true saturation, compared with about 4% of White patients.

Subsequent studies extended and quantified the disparity. Fawzy and colleagues found that among COVID-19 patients, pulse oximetry overestimated arterial saturation by an average of 1.7 percentage points in Asian patients, 1.2 in Black patients, and 1.1 in Hispanic patients relative to White patients, and that this overestimation was associated with delayed or unrecognized eligibility for COVID-19 therapies (Fawzy et al., JAMA Intern Med 2022). A 2025 BMJ analysis found SpO₂ readings 0.6 to 1.5 percentage points higher for patients with darker skin tones (BMJ, 2025). The most comprehensive synthesis to date — Parr and colleagues' 2024 meta-analysis of 15 studies covering 207,464 patients and 732,505 paired SpO₂/SaO₂ measurements — found that Black patients were 67% more likely to experience occult hypoxemia than White patients, with an average 3.1–3.5 percentage-point absolute increase (Parr et al., 2024; Public Citizen comment to FDA-2023-N-4976).

Crucially, the disparity is not uniformly distributed across manufacturers. Masimo's own controlled-desaturation study of its SET devices reported near-equal bias in Black and White volunteers, and Nonin has published equity-focused performance data for its PureSAT technology (Masimo / Springer, 2023; Nonin Medical). But the category-level evidence — and the FDA's position — is that the predicate-based clearance standard as a whole did not require enrollment and accuracy reporting across the full range of skin pigmentation.

FDA's 2025 Draft Guidance: Rewriting the Predicate Bargain

In February 2021, FDA issued a safety communication acknowledging that skin pigmentation is one of several factors that can affect pulse-oximeter accuracy (FDA, 2021). Four years later, on January 7, 2025, the agency released the draft guidance Pulse Oximeters for Medical Purposes: Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations (docket FDA-2023-N-4976), which will, when finalized, supersede the 2013 pulse-oximeter 510(k) guidance (FDA, 2025; FDA press release, 2025).

The draft guidance asks manufacturers to:

• Generate clinical performance data with enrollment across the range of skin pigmentation, using a validated skin-tone measurement (such as individual typology angle) rather than self-reported race
• Report accuracy stratified by skin pigmentation, not only as a pooled average
• Provide labeling that discloses accuracy limitations for patients with darker skin pigmentation

The change matters precisely because the bar was so low before. The 2013 guidance that the new document will supersede required clinical validation studies to enroll as few as two subjects, or 15% of the study pool, with dark skin pigmentation — a minimum that a manufacturer could technically satisfy while leaving most of the accuracy claim unstress-tested across skin tone (Masimo / J Clinical Monitoring & Computing, 2023). FDA's own executive-summary evaluation, presented to its advisory committee, reviewed DQA 510(k) submissions cleared since 2000 and assessed how skin pigmentation was enrolled and reported in those desaturation studies — the direct precursor to the draft guidance (FDA Executive Summary, 2022). An independent JAMA review by Lipnick and colleagues concurred that the guidance addresses a real gap, while noting it could go further on minimum subject counts (Lipnick et al., JAMA 2025).

As FDA CDRH Director Michelle Tarver put it, the recommendations are "based on the best available science to help address concerns of disparate performance of pulse oximeters based on an individual's skin pigmentation" (FDA, 2025). In substance, the guidance converts what was an average-accuracy standard into a subgroup-accuracy standard — and because the category is entirely predicate-based, every future 510(k) that claims equivalence to an older device will have to confront whether that predicate's evidence base meets the new skin-pigmentation expectation.

What This Means for Pulse-Oximeter Manufacturers

1. Audit your predicate chain now. A manufacturer preparing a DQA 510(k) after the guidance is finalized will need to show that its chosen predicate supports — or can be supplemented with — stratified skin-pigmentation performance data. Predicates cleared under the 2013 standard may not.
2. Budget for new clinical evidence. Controlled-desaturation studies with validated skin-tone enrollment across the full pigmentation range are more demanding than the historical average-Arms study. This is the single largest change to the 510(k) cost and timeline for this device family in over a decade.
3. Expect labeling disclosures. Accuracy limitations by skin pigmentation are likely to become required labeling, which has downstream implications for clinical-decision protocols that rely on SpO₂ thresholds.
4. Differentiate on equity evidence. Manufacturers that already hold stratified-accuracy data (Masimo SET, Nonin PureSAT) have a near-term commercial and regulatory advantage; those that do not will need to generate it.

The pulse-oximeter market was built on the efficiency of the 510(k) predicate pathway — 726 clearances, every one of them an equivalence determination. The same efficiency is now the mechanism through which FDA is raising the bar: by changing what a future "substantially equivalent" clearance must demonstrate, the agency is reaching back through the predicate tree to reshape the entire category.

Data sources: FDA 510(k) premarket notification database, FDA Medical Device Recall database, and FDA product classification database; analysis by MedDeviceGuide, run date 2026-06-14. Clinical and regulatory references are cited inline. This article is educational and is not regulatory, quality-system, or clinical advice for a specific product.